Sartorius Stedim Biotech SA
DIM: XPAR (FRA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€949.00 | Vqtt | Stxmnwbw |
Wide-Moat Sartorius Stedim Withstands Slowing COVID-19 Revenue in Q1 With Strong Core Sales Growth
Sartorius Stedim Biotech reported first-quarter earnings that largely met our expectations, and we maintain our EUR 290 fair value estimate and wide moat rating.